Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis

Authors：Li, Sijia; Chen, Xueqin; Hu, Penghua; Wu, Suijing; Ma, Jianchao; Li, Zhuo; Wu, Xiuchuan; Wen, Feng; Fu, Xia; Feng, Zhonglin; Tao, Yiming; Li, Bohou; Fu, Lei; Huang, Renwei; He, Chaosheng; Shi, Wei; Liang, Xinling^*; Liu, Shuangxin^*

Source：Blood Purification, 2022, 51(2): 189-192.

DOI：10.1159/000513423

• Hemodialysis
• Pure red cell aplasia
• Anti-erythropoietin antibody
• Roxadustat

Anemia is a common complication of chronic kidney disease (CKD). Recombinant human erythropoietin (rHu-EPO) is used extensively in patients with CKD. However, anti-erythropoietin (anti-EPO) antibody has been reported during rHu-EPO treatment, which causes pure red cell aplasia (PRCA). We presented a case of 75-year-old man, who underwent hemodialysis for 2 years. He developed PRCA during rHu-EPO treatment. The rHu-EPO was immediately discontinued, and the patient was given roxadustat treatment. After 6 months of roxadustat treatment, the anti-EPO antibody was disappeared, and hemoglobin recovered normal range. The results suggest that roxadustat can be used to treat patients with anti-EPO antibody-mediated PRCA without immunosuppressive therapy.

• Institution
  广东省人民医院